{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:46:55Z","timestamp":1795085215449,"version":"4.10.2"},"reference-count":53,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) develops devastating bone destruction with enhanced bone resorption and suppressed bone formation. In contrast to enhanced osteoclastogenesis, little is known about the mechanism of impaired bone formation in MM. Because a canonical Wingless-type (Wnt) signaling pathway has recently been shown to play an important role in osteoblast differentiation, we examined whether MM cells affect a canonical Wnt pathway to suppress bone formation. Conditioned media from RPMI8226 and U266 MM cell lines and primary MM cells suppressed in vitro mineralization as well as alkaline phosphatase activity in osteoblasts induced by bone morphogenetic protein 2 (BMP-2). These cell lines constitutively produced a soluble Wnt inhibitor, secreted Frizzled-related protein 2 (sFRP-2), but not other Wnt inhibitors including sFRP-1, sFRP-3, and dickkopf 1 (DKK-1) at the protein level. Most MM cells from patients with advanced bone destructive lesions also expressed sFRP-2. Furthermore, exogenous sFRP-2 suppressed osteoblast differentiation induced by BMP-2, and immunodepletion of sFRP-2 significantly restored mineralized nodule formation in vitro, suggesting a predominant role for MM cell-derived sFRP-2 in the impairment of bone formation by MM. Thus, in addition to enhanced osteolysis, MM cells also suppress bone formation at least in part through an inhibition of the canonical Wnt pathway by secreting sFRP-2.<\/jats:p>","DOI":"10.1182\/blood-2004-12-4940","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T00:26:26Z","timestamp":1121819186000},"page":"3160-3165","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":290,"title":["Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2"],"prefix":"10.1182","volume":"106","author":[{"given":"Takashi","family":"Oshima","sequence":"first","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Abe","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Asano","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hara","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kitazoe","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Sekimoto","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Shibata","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Ozaki","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Kido","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021216434191400_REF1","doi-asserted-by":"crossref","unstructured":"Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336: 1657-1664.","DOI":"10.1056\/NEJM199706053362307"},{"key":"2020021216434191400_REF2","doi-asserted-by":"crossref","unstructured":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998;16: 3832-3842.","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"2020021216434191400_REF3","doi-asserted-by":"crossref","unstructured":"Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93: 165-176.","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"2020021216434191400_REF4","doi-asserted-by":"crossref","unstructured":"Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89: 309-319.","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"2020021216434191400_REF5","doi-asserted-by":"crossref","unstructured":"Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98: 11581-11586.","DOI":"10.1073\/pnas.201394498"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98: 3527-3533.","DOI":"10.1182\/blood.V98.13.3527"},{"key":"2020021216434191400_REF7","doi-asserted-by":"crossref","unstructured":"Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood. 2003;101: 2094-2098.","DOI":"10.1182\/blood-2002-09-2684"},{"key":"2020021216434191400_REF8","doi-asserted-by":"crossref","unstructured":"Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100: 2195-2202.","DOI":"10.1182\/blood.V100.6.2195"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96: 671-675.","DOI":"10.1182\/blood.V96.2.671"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest. 2001;108: 1833-1841.","DOI":"10.1172\/JCI200113116"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology (Am Soc Hematol Educ Program). 2002: 214-240.","DOI":"10.1182\/asheducation-2002.1.214"},{"key":"2020021216434191400_REF12","doi-asserted-by":"crossref","unstructured":"Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003;102: 311-319.","DOI":"10.1182\/blood-2002-12-3905"},{"key":"2020021216434191400_REF13","doi-asserted-by":"crossref","unstructured":"Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104: 2484-2491.","DOI":"10.1182\/blood-2003-11-3839"},{"key":"2020021216434191400_REF14","doi-asserted-by":"crossref","unstructured":"Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004;64: 2016-2023.","DOI":"10.1158\/0008-5472.CAN-03-1131"},{"key":"2020021216434191400_REF15","doi-asserted-by":"crossref","unstructured":"Hashimoto T, Abe M, Oshima T, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol. 2004;125: 38-41.","DOI":"10.1111\/j.1365-2141.2004.04864.x"},{"key":"2020021216434191400_REF16","doi-asserted-by":"crossref","unstructured":"Nusse R. WNT targets. Repression and activation. Trends Genet. 1999;15: 1-3.","DOI":"10.1016\/S0168-9525(98)01634-5"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Moon RT, Brown JD, Torres M. et al. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet. 1997;13: 157-162.","DOI":"10.1016\/S0168-9525(97)01093-7"},{"key":"2020021216434191400_REF18","doi-asserted-by":"crossref","unstructured":"Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107: 513-523.","DOI":"10.1016\/S0092-8674(01)00571-2"},{"key":"2020021216434191400_REF19","doi-asserted-by":"crossref","unstructured":"Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11: 3286-3305.","DOI":"10.1101\/gad.11.24.3286"},{"key":"2020021216434191400_REF20","doi-asserted-by":"crossref","unstructured":"Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and function of signal transduction by the Wnt\/beta-catenin and Wnt\/Ca2+ pathways. Oncogene. 1999;18: 7860-7872.","DOI":"10.1038\/sj.onc.1203245"},{"key":"2020021216434191400_REF21","doi-asserted-by":"crossref","unstructured":"Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002;157: 303-314.","DOI":"10.1083\/jcb.200201089"},{"key":"2020021216434191400_REF22","doi-asserted-by":"crossref","unstructured":"Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70: 11-19.","DOI":"10.1086\/338450"},{"key":"2020021216434191400_REF23","doi-asserted-by":"crossref","unstructured":"Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346: 1513-1521.","DOI":"10.1056\/NEJMoa013444"},{"key":"2020021216434191400_REF24","doi-asserted-by":"crossref","unstructured":"Abe M, Shintani Y, Eto Y, et al. Potent induction of activin A secretion from monocytes and bone marrow stromal fibroblasts by cognate interaction with activated T cells. J Leukoc Biol2002;72: 347-352.","DOI":"10.1189\/jlb.72.2.347"},{"key":"2020021216434191400_REF25","doi-asserted-by":"crossref","unstructured":"Matsumoto T, Igarashi C, Takeuchi Y, et al. Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells. Bone. 1991;12: 27-32.","DOI":"10.1016\/8756-3282(91)90051-J"},{"key":"2020021216434191400_REF26","doi-asserted-by":"crossref","unstructured":"Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev. 2000;21: 393-411.","DOI":"10.1210\/edrv.21.4.0403"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Gallea S, Lallemand F, Atfi A, et al. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone. 2001;28: 491-498.","DOI":"10.1016\/S8756-3282(01)00415-X"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Spinella-Jaegle S, Roman-Roman S, Faucheu C, et al. Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation. Bone. 2001;29: 323-330.","DOI":"10.1016\/S8756-3282(01)00580-4"},{"key":"2020021216434191400_REF29","doi-asserted-by":"crossref","unstructured":"Suzawa M, Takeuchi Y, Fukumoto S, et al. Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. Endocrinology. 1999;140: 2125-2133.","DOI":"10.1210\/endo.140.5.6704"},{"key":"2020021216434191400_REF30","doi-asserted-by":"crossref","unstructured":"Zimmerman LB, De Jesus-Escobar JM, Harland RM. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell. 1996;86: 599-606.","DOI":"10.1016\/S0092-8674(00)80133-6"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Piccolo S, Sasai Y, Lu B, De Robertis EM. Dorsoventral patterning in Xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell. 1996;86: 589-98.","DOI":"10.1016\/S0092-8674(00)80132-4"},{"key":"2020021216434191400_REF32","doi-asserted-by":"crossref","unstructured":"Fainsod A, Deissler K, Yelin R, et al. The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4. Mech Dev. 1997;63: 39-50.","DOI":"10.1016\/S0925-4773(97)00673-4"},{"key":"2020021216434191400_REF33","doi-asserted-by":"crossref","unstructured":"Bain G, Muller T, Wang X, Papkoff J. Activated beta-catenin induces osteoblast differentiation of C3H10T1\/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun. 2003;301: 84-91.","DOI":"10.1016\/S0006-291X(02)02951-0"},{"key":"2020021216434191400_REF34","doi-asserted-by":"crossref","unstructured":"Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res. 2003;18: 1842-1853.","DOI":"10.1359\/jbmr.2003.18.10.1842"},{"key":"2020021216434191400_REF35","doi-asserted-by":"crossref","unstructured":"Fischer L, Boland G, Tuan RS. Wnt-3A enhances bone morphogenetic protein-2-mediated chondrogenesis of murine C3H10T1\/2 mesenchymal cells. J Biol Chem. 2002;277: 30870-30878.","DOI":"10.1074\/jbc.M109330200"},{"key":"2020021216434191400_REF36","doi-asserted-by":"crossref","unstructured":"Fischer L, Boland G, Tuan RS. Wnt signaling during BMP-2 stimulation of mesenchymal chondrogenesis. J Cell Biochem. 2002;84: 816-831.","DOI":"10.1002\/jcb.10091"},{"key":"2020021216434191400_REF37","doi-asserted-by":"crossref","unstructured":"Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116: 2627-2634.","DOI":"10.1242\/jcs.00623"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Roman-Roman S, Shi DL, Stiot V, et al. Murine Frizzled-1 behaves as an antagonist of the canonical Wnt\/beta-catenin signaling. J Biol Chem. 2004;279: 5725-5733.","DOI":"10.1074\/jbc.M309233200"},{"key":"2020021216434191400_","doi-asserted-by":"crossref","unstructured":"Bodine PV, Zhao W, Kharode YP, et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004;18: 1222-1237.","DOI":"10.1210\/me.2003-0498"},{"key":"2020021216434191400_REF40","doi-asserted-by":"crossref","unstructured":"Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays. 2002;24: 811-820.","DOI":"10.1002\/bies.10136"},{"key":"2020021216434191400_REF41","doi-asserted-by":"crossref","unstructured":"Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349: 2483-2494.","DOI":"10.1056\/NEJMoa030847"},{"key":"2020021216434191400_REF42","doi-asserted-by":"crossref","unstructured":"Feliers D, Woodruff K, Abboud S. Potential role of insulin-like growth factor binding protein-4 in the uncoupling of bone turnover in multiple myeloma. Br J Haematol. 1999;104: 715-722.","DOI":"10.1046\/j.1365-2141.1999.01243.x"},{"key":"2020021216434191400_REF43","doi-asserted-by":"crossref","unstructured":"Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005;106: 1407-1414.","DOI":"10.1182\/blood-2005-03-1080"},{"key":"2020021216434191400_REF44","doi-asserted-by":"crossref","unstructured":"Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003;129: 199-221.","DOI":"10.1007\/s00432-003-0431-0"},{"key":"2020021216434191400_REF45","doi-asserted-by":"crossref","unstructured":"Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14: 1837-1851.","DOI":"10.1101\/gad.14.15.1837"},{"key":"2020021216434191400_REF46","doi-asserted-by":"crossref","unstructured":"Qiang YW, Endo Y, Rubin JS, Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene. 2003;22: 1536-1545.","DOI":"10.1038\/sj.onc.1206239"},{"key":"2020021216434191400_REF47","doi-asserted-by":"crossref","unstructured":"Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004;101: 6122-6127.","DOI":"10.1073\/pnas.0305855101"},{"key":"2020021216434191400_REF48","unstructured":"Yaccoby S, Wezeman MJ, Henderson A, et al. Mesenchymal stem cells differentiate into osteogenic cells and inhibit a subset of myeloma in vivo [abstract]. Blood. 2003;102: 445a. Abstract 1627."},{"key":"2020021216434191400_REF49","doi-asserted-by":"crossref","unstructured":"Roth W, Wild-Bode C, Platten M, et al. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene. 2000;19: 4210-4220.","DOI":"10.1038\/sj.onc.1203783"},{"key":"2020021216434191400_REF50","doi-asserted-by":"crossref","unstructured":"Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423: 409-414.","DOI":"10.1038\/nature01593"},{"key":"2020021216434191400_REF51","doi-asserted-by":"crossref","unstructured":"Austin TW, Solar GP, Ziegler FC, Liem L, Matthews W. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood. 1997;89: 3624-3635.","DOI":"10.1182\/blood.V89.10.3624"},{"key":"2020021216434191400_REF52","doi-asserted-by":"crossref","unstructured":"Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the Wnt gene family in human hematopoiesis. Blood. 1998;92: 3189-3202.","DOI":"10.1182\/blood.V92.9.3189"},{"key":"2020021216434191400_REF53","doi-asserted-by":"crossref","unstructured":"van de Wetering M, de Lau W, Clevers H. WNT signaling and lymphocyte development. Cell. 2002;109(suppl): S13\u201319.","DOI":"10.1016\/S0092-8674(02)00709-2"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/9\/3160\/1635840\/zh802105003160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/9\/3160\/1635840\/zh802105003160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T19:46:06Z","timestamp":1683143166000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/9\/3160\/21915\/Myeloma-cells-suppress-bone-formation-by-secreting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-12-4940","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,1]]}}}